Interaction of Vitamin D Supplements and Marine n-3 Fatty Acids on Digestive Tract Cancer Prognosis

Soichiro Fukuzato,Hironori Ohdaira,Yutaka Suzuki,Mitsuyoshi Urashima

DOI: https://doi.org/10.3390/nu16070921

IF: 5.9

2024-03-23

Nutrients

Abstract:A meta-analysis suggested that marine n-3 polyunsaturated fatty acids (PUFAs), e.g., eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), might reduce cancer mortality. However, a randomized clinical trial of marine n-3 PUFA and vitamin D supplementation failed to verify this benefit. This study aimed to investigate the potential interaction between vitamin D supplementation and serum EPA and DHA levels. This post hoc analysis of the AMATERASU trial (UMIN000001977), a randomized controlled trial (RCT), included 302 patients with digestive tract cancers divided into two subgroups stratified by median serum levels of EPA + DHA into higher and lower halves. The 5-year relapse-free survival (RFS) rate was significantly higher in the higher half (80.9%) than the lower half (67.8%; hazard ratio (HR), 2.15; 95% CI, 1.29–3.59). In the patients in the lower EPA + DHA group, the 5-year RFS was significantly higher in the vitamin D (74.9%) than the placebo group (49.9%; HR, 0.43; 95% CI, 0.24–0.78). Conversely, vitamin D had no effect in the higher half, suggesting that vitamin D supplementation only had a significant interactive effect on RFS in the lower half (p for interaction = 0.03). These results suggest that vitamin D supplementation may reduce the risk of relapse or death by interacting with marine n-3 PUFAs.

nutrition & dietetics

What problem does this paper attempt to address?

The main issue this paper attempts to address is the potential interaction between vitamin D supplements and marine n-3 polyunsaturated fatty acids (such as EPA and DHA) on the prognosis of patients with gastrointestinal cancer. Specifically, the study aims to investigate whether vitamin D supplements can reduce the risk of cancer recurrence or death through interaction with blood levels of EPA and DHA.

### Research Background
1. **Marine n-3 Polyunsaturated Fatty Acids (PUFAs)**:
- Marine n-3 PUFAs (such as EPA and DHA) are believed to reduce the risk of cardiovascular diseases, but their impact on cancer mortality has not been confirmed in randomized clinical trials.
- A large-scale VITAL randomized controlled trial showed that marine n-3 PUFAs supplements did not reduce cancer mortality.

2. **Vitamin D Supplements**:
- Multiple studies suggest that vitamin D supplements may reduce cancer mortality.
- In the AMATERASU trial, vitamin D supplements significantly improved the 5-year recurrence-free survival (RFS) rate in patients with gastrointestinal cancer.
- Other studies also support the potential role of vitamin D supplements in reducing cancer mortality.

### Research Objectives
- **Primary Objective**: To explore the interaction between vitamin D supplements and blood levels of EPA and DHA, and whether this interaction can affect the risk of recurrence or death in patients with gastrointestinal cancer.
- **Specific Goals**: To evaluate the differential effects of vitamin D supplements in different EPA and DHA level groups by analyzing the remaining samples from the AMATERASU trial.

### Research Methods
- **Study Design**: Retrospective analysis of data from the AMATERASU trial, a randomized, double-blind, placebo-controlled study conducted in Japan.
- **Participants**: 417 patients with stage I to III gastrointestinal cancer, with serum samples available for PUFA measurement from 302 patients.
- **Primary Outcome**: Time to recurrence or death.
- **Statistical Analysis**: Cox proportional hazards model to analyze the interaction between vitamin D supplements and PUFA levels.

### Main Findings
- **Group with Higher EPA + DHA Levels**: 5-year RFS was significantly higher than the lower group (80.9% vs 67.8%).
- **Group with Lower EPA + DHA Levels**: Vitamin D supplements significantly improved 5-year RFS (74.9% vs 49.9%), while there was no significant effect in the higher group.
- **Interaction**: There was a significant interaction between vitamin D supplements and the group with lower EPA + DHA levels (p-value = 0.03).

### Conclusion
- **Main Conclusion**: Vitamin D supplements may reduce the risk of recurrence or death in patients with gastrointestinal cancer through interaction with blood levels of EPA and DHA, particularly in patients with lower EPA + DHA levels.

### Significance
- **Clinical Significance**: This study provides new evidence for the use of vitamin D supplements in specific patient populations, helping to optimize treatment strategies for patients with gastrointestinal cancer.
- **Future Research Directions**: Further prospective studies are needed to validate this finding and explore its applicability in other populations.